OptimizeRx (NASDAQ:OPRX) Announces Quarterly Earnings Results

OptimizeRx (NASDAQ:OPRX) issued its earnings results on Wednesday. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.11), Zacks reports. OptimizeRx had a negative return on equity of 4.92% and a negative net margin of 27.41%. OptimizeRx updated its FY 2025 guidance to EPS.

OptimizeRx Trading Up 59.9 %

Shares of NASDAQ OPRX opened at $6.62 on Wednesday. The business has a 50-day moving average price of $5.41 and a two-hundred day moving average price of $5.92. The firm has a market capitalization of $121.97 million, a PE ratio of -4.70 and a beta of 1.31. OptimizeRx has a one year low of $3.78 and a one year high of $14.80. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29.

Insider Activity

In related news, CEO William J. Febbo bought 20,000 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were bought at an average cost of $5.01 per share, for a total transaction of $100,200.00. Following the completion of the acquisition, the chief executive officer now directly owns 601,253 shares in the company, valued at approximately $3,012,277.53. This represents a 3.44 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

OPRX has been the subject of several recent research reports. JMP Securities reaffirmed a “market outperform” rating and set a $8.00 price target on shares of OptimizeRx in a report on Thursday, February 6th. Barclays decreased their price target on shares of OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating on the stock in a report on Thursday, November 14th. Stifel Nicolaus reduced their target price on OptimizeRx from $13.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. William Blair reiterated an “outperform” rating on shares of OptimizeRx in a research note on Thursday, November 14th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $6.00 price objective (down from $7.00) on shares of OptimizeRx in a report on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $9.06.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.